Your browser doesn't support javascript.
loading
Distinguishing COVID-19 infection and vaccination history by T cell reactivity
Esther Dawen Yu; Eric Wang; Emily Garrigan; Benjamin Goodwin; Aaron Sutherland; James Chang; Rosa Isela Galvez; Jose Mateus; Stephen A Rawlings; Davey M Smith; April Frazier; Daniela Weiskopf; Jennifer M Dan; Shane Crotty; Alba Grifoni; Alessandro Sette; Ricardo da Silva Antunes.
  • Esther Dawen Yu; La Jolla Institute for Immunology
  • Eric Wang; La Jolla Institue for Immunology
  • Emily Garrigan; La Jolla Institue for Immunology
  • Benjamin Goodwin; La Jolla Institute for Immunology
  • Aaron Sutherland; La Jolla Institute for Immunology
  • James Chang; La Jolla Institute for Immunology
  • Rosa Isela Galvez; La Jolla Institute for Immunology
  • Jose Mateus; La Jolla Institute for Immunology
  • Stephen A Rawlings; University of California, San Diego
  • Davey M Smith; University of California, San Diego
  • April Frazier; La Jolla Institute for Immunology
  • Daniela Weiskopf; La Jolla Institute for Immunology
  • Jennifer M Dan; La jolla Institute for Immunology
  • Shane Crotty; La Jolla Institute For Immunology (LJI)
  • Alba Grifoni; La Jolla Institute for Immunology
  • Alessandro Sette; La Jolla Institute for Immunology
  • Ricardo da Silva Antunes; La Jolla Institute for Immunology
Preprint En | PREPRINT-BIORXIV | ID: ppbiorxiv-472874
SARS-CoV-2 infection and COVID-19 vaccines elicit memory T cell responses. Here, we report the development of two new pools of Experimentally-defined T cell epitopes derived from the non-spike Remainder of the SARS-CoV-2 proteome (CD4RE and CD8RE). The combination of T cell responses to these new pools and Spike (S) were used to discriminate four groups of subjects with different SARS-CoV-2 infection and COVID-19 vaccine status non-infected, non-vaccinated (I-V-); infected and non-vaccinated (I+V-); infected and then vaccinated (I+V+); and non-infected and vaccinated (I-V+). The overall classification accuracy based on 30 subjects/group was 89.2% in the original cohort and 88.5% in a validation cohort of 96 subjects. The T cell classification scheme was applicable to different mRNA vaccines, and different lengths of time post-infection/post-vaccination. T cell responses from breakthrough infections (infected vaccinees, V+I+) were also effectively segregated from the responses of vaccinated subjects using the same classification tool system. When all five groups where combined, for a total of 239 different subjects, the classification scheme performance was 86.6%. We anticipate that a T cell-based immunodiagnostic scheme able to classify subjects based on their vaccination and natural infection history will be an important tool for longitudinal monitoring of vaccination and aid in establishing SARS-CoV-2 correlates of protection.

cc_by_nc_nd
...